Pharmaceutical Executive June 20, 2024
Data from an early phase trial published in Nature found that Parkinson disease patients treated with UB-312 experienced significant improvements in motor functions and daily living.
Approximately 90,000 people are diagnosed with Parkinson disease (PD) in the United States each year. While there are a number of treatments on the market to support patients with PD, there currently are no approved disease-modifying therapies. In a study published in Nature, a Phase I clinical trial investigating the safety, tolerability and immunogenicity of UB-312—a novel, active immunotherapeutic—found that patients experienced considerable improvements in motor function and overall cognitive health.1,2
The investigators noted that treatments targeting a toxic species of α-Synuclein—a presynaptic neuronal protein that has been associated genetically and neuropathologically with PD—seek...
Today's Sponsors
Today's Sponsor